Trial finds coronary bioadaptor offers a significant reduction in adverse clinical events

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as a contemporary drug-eluting stent (DES) with regard to target lesion and target vessel failure outcomes at one year in a large, broad clinical population. This late breaking research was presented in a Hot Line session Sept. 2 at this year’s ESC Congress 2024.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup